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available. Either method will indicate the clinically effective dosage range for the particular type of patient included in the trial.
Of particular importance is the introduction of chemical and biological metheas of potency assay where results can be used to grade senna preparations in terms of their likely effect on the constipated bowel in humans.
We would emphasize the agreement between the various forms of assessment, laboratory and clinical, in indicating gross disparities between similar doses of apparently identical standard B.P. syrups. The laboratory tests confirm earlier suggestions of the serious deterioration which may take place in such aqueous preparations. Again, average doses of the two B.P. syrups tested clinically gave no better results than inert syrups. On the other hand, the dry granular preparation tested (senokot) proved to be chemically stable and to have the potent clinical effect which had been predicted from the results of both chemical and biological assay.
Summary and Conclusions
The design and conduct of controlled clinical trials of the therapeutic effect of different senna preparations are described. The results obtained in constipated patients of different clinical types have been compared with the potencies estimated from chemical assay of sennoside content and biological assay based on the laxative action in mice. It was concluded that:
(1) Laxatives could be effectively graded by simple clinical trials in both short-stay hospital patients and the more chronically constipated elderly sick. (2) Clinical response rates are in general agreement with the results of both types of laboratory assay methods. Not only do apparently identical B.P. preparations of syrup of senna differ widely in their therapeutic effect, but, at average doses, the B.P. syrups tested were no better than inert controls. Chemical assay confirmed previous indications of deterioration in aqueous B.P. preparations. (3) A dry granular preparation of senna pod (senokot), used in dosages usually prescribed, proved to be chemically stable and to have a potent laxative effect.
We should like to thank the sisters in charge of the wards (Ryan, 1951) . A number of favourable reports have now been published (British Encyclopaedia of Medical Practice, 1956 ) and a preliminary trial suggested that senokot might be suitable for use as a routine laxative for puerperal women (Duncan, 1953 Enema required .
.. .
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Design of the Trial All patients in puerperal ward A were given, as a routine laxative, tab. extract cascara B.P., 6 gr. (0.4 g.), on the morning of the third puerperal day. No further laxative or enema was given for 48 hours.
In puerperal ward B exactly the same routine was followed except that the laxative used was "senokot" granules, 2 teaspoonfuls (equivalent to 11 gr. (0.7 g.) of senna pod). Patients who had been delivered by the abdominal route and 12 patients whose bowels moved spontaneously before the third morning were excluded from the trial. No other exceptions were made.
The interval between administration and bowel movement, and the nature of the first motion, were recorded.
The patients whose bowels moved within 24 hours of the dose were regarded as having shown a positive response, and in these the number of bowel movements within the period was noted. These objective observations were made by senior members of the nursing staff. Subjective impressions, such as the severity of colic, were more difficult to assess.
Comparison of the Two Groups
The fact that the two groups are comparable in respect of parity, nature of delivery, and previous history in relation to aperients is shown by Table II . (0.13-0.5 g.) (the dose used was 6 gr. (0.4 g.), which is three-quarters of the maximum B.P. dose) and of senna pod B.P. is 10-30 gr. (0.65-2 g.) (the dose used was equivalent to 11 gr. (0.7 g.), which is one-third of the maximum B.P. dose). The laxative effect should therefore have been greater rather than less in the cascara series. The reason for this discrepancy appears to lie in the fact that tab. extract cascara B.P. is unstandardized and contains only part of the original activity of the bark (Fairbairn and Mahran, 1953) , whereas senokot is standardized and contains 100% activity of senna pod (Fairbairn and Michaels, 1950 No untoward side-effects of the laxatives were noticed apart from gripes. The fact that a higher proportion of the senokot series had gripes is thought to be due to overdosage, because for the purpose of the trial it was necessary to give the same dose to all patients. Further experience with senokot has shown that an occasional patient experiences severe gripes in spite of smaller dosage, but this has been so infrequent that it has not detracted from the advantages of the drug. The majority of patients expressed the opinion that they preferred senokot to other laxatives which they had used in the past. This might be attributed to the novel form of the preparation in chocolateflavoured granules. Senokot is also available, however, in tablet form, and a further series of 138 patients was studied under the same trial conditions with the exception that granules were replaced by tablets. The results of this further trial are so similar to those reported above that they are not given in detail. More than half of these patients said that they preferred senna to other laxatives they had used.
The continued use of senokot since the trial was completed has confirmed that it is a very satisfactory laxative for puerperal women. Its value during pregnancy is much more difficult to subject to a clinical trial, but it seems very satisfactory for this purpose. A few patients complaining of severe morning sickness have improved dramatically following regular administration of senokot. The question whether senna is more effective in this respect than other laxatives will require further study.
Summary
In a series of 100 puerperal women who were given no laxative in the puerperium only 26 had spontaneous bowel movements by the end of the third day, but 71 had had spontaneous motions by the end of the fifth puerperal day. In a elinical trial, extract of cascara in a dose of 6 gr. (0.4 g.) (three-quarters of the pharmacopoeial maximum) was compared with a standardized preparation of senna in a dose of 11 gr. (0.7 g.) (one-third of the pharmacopoeial maximum). With the dosages used the senna (" senokot ") was shown to be a more effective laxative.
In the course of the trial it was noted that, of 290 women, 66 had been taking laxatives regularly before they became pregnant and that 43 had taken liquid paraffin regularly during their pregnancy.
I thank Miss G. Perkins and Rynearson (1952 ), Hart (1953 ), Querido et al. (1954 , Whittaker and Whitehead (1954) , and others advocate a wider range of substitution therapy and include deoxycortone acetate (D.C.A.), testosterone, and thyroid in addition to cortisone.
With the object of determining the simplest and most effective method of treatment for hypopituitarism, four patients suffering from post-partum pituitary insufficiency were studied as out-patients, and their response to traditional methods of therapy, supplemented with cortisone, was compared with their behaviour when treatment was continued on cortisone alone.
Method
The four patients were treated for periods ranging from 8 to 20 months on combined therapy consisting of D.C.A., sodium chloride, methyltestosterone, stilboestrol, thyroid, and cortisone (combined therapy), and subsequently for periods of 7 to 11 months on cortisone alone. Each patient was carefully assessed at three stages: before treatment started; when D.C.A., salt, testosterone, stilboestrol, and thyroid were withdrawn; and, finally, at the end of the trial period on cortisone. As a safeguard, each patient was interviewed monthly or more often as necessary, and the blood pressure and weight were recorded. At the three major examinations special attention was paid to the following points: energy and capacity for work and recreation; emotional tone, sense of well-being, and mental state; libido; menstruation; incidence and severity of infections and crises; tolerance of cold; weight and blood pressure; condition of hair and skin; and certain laboratory investigations. The decision to start the trial with combined therapy first, followed by cortisone alone, was made partly because we felt that the withdrawal of a drug providing a measure of relief of symptoms would be more readily noticed by the patients. An additional reason was that several patients were already on a modified form of combined treatment, so it was decided to extend and proceed with this aspect first.
Clinical details of the four patients together with details of treatment given are recorded in Table I .
Results of Treatment Energy and Capacity for Work.-Profound weakness and lack of energy were characteristic of each case before the clinical trial started. A remarkable recovery was evident with combined treatment, and this improvement was maintained without any deterioration in three cases on cortisone alone. One patient felt well enough to resume her work as a weaver in addition to household duties. Another housewife was able to nurse an invalid relative living at some distance from her home. In the fourth case there was reappearance of asthenia and intolerance to cold, and thyroid had to be restarted seven weeks after its withdrawal.
Emotional Tone, Sense of Well-being, and Mental State. -The patients were depressed and low in spirits before treatment began, and mentally dull or sluggish. All returned apparently to normal on combined therapy, and no change was noticed by the patients, relatives, or physicians when therapy was continued on cortisone alone, except in Case 2, where mental sluggishness, depression, and misery were quickly apparent despite additional cortisone dosage. These symptoms were attributed to lack of thyroid, and they quickly regressed when this was restarted.
Libido.-This was lost in all subjects, and in two there was no improvement throughout the trial with either therapy, but libido had always been weak in these two women. However, one patient noticed some improvement in libido and sexual response with combined treatment, an improvement little altered with cortisone alone. Another patient reported almost immediate improvement in libido and return of orgasm on combined therapy. This was fully maintained with cortisone.
Menstruation.-All had complete amenorrhoea from the onset of their illness until three reported a three to four-day menstrual staining or bleeding during the periods of cyclical stilboestrol withdrawal. One patient (Case 4) did not take stilboestrol very regularly and did not menstruate.. There was complete amenorrhoea again when stilboestrol was withheld.
Incidence and Severity of Infections and Crises.-One patient was initially admitted to hospital in coma. The other three had no history of frequent infections or crises before treatment. Since the start of treatment all have remained well and no difference has been apparent between the two forms of therapy.
